Trial Profile
A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 May 2017
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Aclarubicin; Cytarabine; Etoposide; Filgrastim; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 30 May 2017 New trial record